Oral type II collagen treatment in early rheumatoid arthritis: a double-blind, placebo-controlled, randomized trial
Sieper J, Kary S, Sorensen H, Alten R, Eggens U, Huge W, Hiepe F, Kuhne A, Listing J, Ulbrich N, Braun J, Zink A, Mitchison NA
Published in Arthritis & Rheumatism
Methodology
Double-blind, placebo-controlled randomized trial of oral bovine type II collagen at two doses for 12 weeks in early rheumatoid arthritis.
Key Findings
No significant differences in disease activity between oral type II collagen and placebo groups.
Conclusions
Oral type II collagen showed no benefit over placebo in early rheumatoid arthritis.
Limitations
Short 12-week duration, moderate sample, older trial with pre-modern outcome measures.
Supplements Studied
No significant differences in disease activity between oral type II collagen and placebo groups.
Outcomes Measured
Oral type II collagen did not differ from placebo on disease activity in early rheumatoid arthritis.
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.